At the recent ASCO event, ivonescimab, a drug developed by Akeso and Summit, was highlighted for its ability to extend survival in patients with squamous cell lung cancer.
While the results are promising, medical professionals are advocating for follow-up studies that include a more diverse population to ensure the drug's efficacy across different demographics.
The development of ivonescimab marks a significant advancement in lung cancer treatment originating from China, but further research will be crucial in validating its benefits.